compname says q4 sales grew 12% to $1.33 billion, up 13% on an underlying basis.
q4 sales grew 12% to $1.33 billion, up 13% on an underlying basis.
fy 2022 financial guidance unchanged.
q4 earnings per share was $0.53; q4 adjusted earnings per share was $0.51.
qtrly tavr sales of $872 million, up 12%.
tavr sales negatively impacted in last several weeks of q4 due to impact omicron had on hospital resources in u.s.
co is reaffirming 2022 sales guidance for all product groups.
sees q1 total sales between $1.27 and $1.35 billion, and q1 adjusted earnings per share of $0.54 to $0.62.
believe that opportunity to serve our patients will nearly double between now and 2028.
